SCA
AEGR

Southpoint Capital Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Southpoint Capital Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-75,000
Closed -$6.43M – 42
2013
Q3 		$6.43M Sell
75,000
-125,000
-63% -$10.6M 0.36% 26
2013
Q2 		$12.7M Buy
+200,000
New +$10.6M 0.78% 25

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Southpoint Capital Advisors's AEGR Position: Q4 2013 in Review

Southpoint Capital Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 75,000 shares — an estimated $6.43M sold.

Southpoint Capital Advisors first reported a position in AEGR in Q2 2013 and held it in 2 quarters. The position peaked at $12.7M in Q2 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Southpoint Capital Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Southpoint Capital Advisors sold 75,000 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $6.43M.
  • Southpoint Capital Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Southpoint Capital Advisors's Aegerion Pharmaceuticals position peaked at $12.7M in Q2 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Southpoint Capital Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.